|
1
|
Jiang GM, Wang HS, Zhang F, Zhang KS, Liu
ZC, Fang R, Wang H, Cai SH and Du J: Histone deacetylase inhibitor
induction of epithelial-mesenchymal transitions via up-regulation
of Snail facilitates cancer progression. Biochim Biophys Acta.
1833:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu W, Liu H, Liu ZG, Wang HS, Zhang F,
Wang H, Zhang J, Chen JJ, Huang HJ, Tan Y, et al: Histone
deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation
and stabilization of Snail to promote metastasis of hepatoma cells.
Cancer Lett. 420:1–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Di Costanzo A, Del Gaudio N, Conte L,
Dell'Aversana C, Vermeulen M, de The H, Migliaccio A, Nebbioso A
and Altucci L: The HDAC inhibitor SAHA regulates CBX2 stability via
a SUMO-triggered ubiquitin-mediated pathway in leukemia. Oncogene.
37:2559–2572. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ni X, Li L and Pan G: HDAC
inhibitor-induced drug resistance involving ATP-binding cassette
transporters (Review). Oncol Lett. 9:515–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valdez BC, Nieto Y, Murray D, Li Y, Wang
G, Champlin RE and Andersson BS: Epigenetic modifiers enhance the
synergistic cytotoxicity of combined nucleoside analog-DNA
alkylating agents in lymphoma cell lines. Exp Hematol. 40:800–810.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nieto Y, Valdez BC, Thall PF, Ahmed S,
Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, et
al: Vorinostat combined with high-dose gemcitabine, busulfan, and
melphalan with autologous stem cell transplantation in patients
with refractory lymphomas. Biol Blood Marrow Transplant.
21:1914–1920. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teo EC, Valdez BC, Ji J, Li Y, Liu Y,
Brammer JE, Hosing C, Nieto Y, Champlin RE and Andersson BS:
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine,
panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma.
57:2644–2652. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fukuda Y and Schuetz JD: ABC transporters
and their role in nucleoside and nucleotide drug resistance.
Biochem Pharmacol. 83:1073–1083. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen ZS and Tiwari AK: Multidrug
resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic
diseases. FEBS J. 278:3226–3245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu YR, Liang L, Zhao JM, Zhang Y, Zhang
M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al: Twist1 confers
multidrug resistance in colon cancer through upregulation of
ATP-binding cassette transporters. Oncotarget. 8:52901–52912. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maia RC, Vasconcelos FC, Souza PS and
Rumjanek VM: Towards comprehension of the ABCB1/P-glycoprotein role
in chronic myeloid leukemia. Molecules. 23:1192018. View Article : Google Scholar
|
|
12
|
Sharom FJ: The P-glycoprotein multidrug
transporter. Essays Biochem. 50:161–178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borst P, Evers R, Kool M and Wijnholds J:
A family of drug transporters: The multidrug resistance-associated
proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dean M, Hamon Y and Chimini G: The human
ATP-binding cassette (ABC) transporter superfamily. J Lipid Res.
42:1007–1017. 2001.PubMed/NCBI
|
|
15
|
Wang J, Yunyun Z, Wang L, Chen X and Zhu
Z: ABCG2 confers promotion in gastric cancer through modulating
downstream CRKL in vitro combining with biostatistics mining.
Oncotarget. 8:5256–5267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaehler M, Ruemenapp J, Gonnermann D,
Nagel I, Bruhn O, Haenisch S, Ammerpohl O, Wesch D, Cascorbi I and
Bruckmueller H: MicroRNA-212/ABCG2-axis contributes to development
of Imatinib-resistance in leukemic cells. Oncotarget.
8:92018–92031. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ling V: Multidrug resistance: Molecular
mechanisms and clinical relevance. Cancer Chemother Pharmacol. 40
(Suppl):S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cole SP and Deeley RG: Transport of
glutathione and glutathione conjugates by MRP1. Trends Pharmacol
Sci. 27:438–446. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Valdez BC, Li Y, Murray D, Brammer JE, Liu
Y, Hosing C, Nieto Y, Champlin RE and Andersson BS: Differential
effects of histone deacetylase inhibitors on cellular drug
transporters and their implications for using epigenetic modifiers
in combination chemotherapy. Oncotarget. 7:63829–63838. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Witt O, Deubzer HE, Milde T and Oehme I:
HDAC family: What are the cancer relevant targets? Cancer Lett.
277:8–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paumi CM, Ledford BG, Smitherman PK,
Townsend AJ and Morrow CS: Role of multidrug resistance protein 1
(MRP1) and glutathione S-transferase A1-1 in alkylating agent
resistance. Kinetics of glutathione conjugate formation and efflux
govern differential cellular sensitivity to chlorambucil versus
melphalan toxicity. J Biol Chem. 276:7952–7956. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao JJ, Huang Y, Dai Z, Sadee W, Chen J,
Liu S, Marcucci G, Byrd J, Covey JM, Wright J, et al:
Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-
ethylidene]- 4,21-diisopropyl- 2-oxa-12,13-dithia-5,8,20,23-
tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is
mediated by reversible MDR1 induction in human cancer cell lines. J
Pharmacol Exp Ther. 314:467–475. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim H, Kim SN, Park YS, Kim NH, Han JW,
Lee HY and Kim YK: HDAC inhibitors downregulate MRP2 expression in
multidrug resistant cancer cells: Implication for
chemosensitization. Int J Oncol. 38:807–812. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fedier A, Dedes KJ, Imesch P, Von Bueren
AO and Fink D: The histone deacetylase inhibitors suberoylanilide
hydroxamic (Vorinostat) and valproic acid induce irreversible and
MDR1-independent resistance in human colon cancer cells. Int J
Oncol. 31:633–641. 2007.PubMed/NCBI
|
|
27
|
Tabe Y, Konopleva M, Contractor R, Munsell
M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J and
Andreeff M: Up-regulation of MDR1 and induction of doxorubicin
resistance by histone deacetylase inhibitor depsipeptide (FK228)
and ATRA in acute promyelocytic leukemia cells. Blood.
107:1546–1554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim YK, Kim NH, Hwang JW, Song YJ, Park
YS, Seo DW, Lee HY, Choi WS, Han JW and Kim SN: Histone deacetylase
inhibitor apicidin-mediated drug resistance: Involvement of
P-glycoprotein. Biochem Biophys Res Commun. 368:959–964. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin S and Scotto KW: Transcriptional
regulation of the MDR1 gene by histone acetyltransferase and
deacetylase is mediated by NF-Y. Mol Cell Biol. 18:4377–4384. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Robey RW, Zhan Z, Piekarz RL, Kayastha GL,
Fojo T and Bates SE: Increased MDR1 expression in normal and
malignant peripheral blood mononuclear cells obtained from patients
receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer
Res. 12:1547–1555. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eyal S, Lamb JG, Smith-Yockman M, Yagen B,
Fibach E, Altschuler Y, White HS and Bialer M: The antiepileptic
and anticancer agent, valproic acid, induces P-glycoprotein in
human tumour cell lines and in rat liver. Br J Pharmacol.
149:250–260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Huang C, Zhao L, Zhang H, Yang JM,
Luo P, Zhan BX, Pan Q, Li J and Wang BL: Histone deacetylase
inhibitors regulate P-gp expression in colorectal cancer via
transcriptional activation and mRNA stabilization. Oncotarget.
7:49848–49858. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karthikeyan S and Hoti SL: Development of
fourth generation ABC inhibitors from natural products: A novel
approach to overcome cancer multidrug resistance. Anticancer Agents
Med Chem. 15:605–615. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuang YH, Shen T, Chen X, Sodani K,
Hopper-Borge E, Tiwari AK, Fu LW and Chen ZS: Lapatinib and
erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated
multidrug resistance. Biochem Pharmacol. 79:154–161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kelner MJ, McMorris TC, Rojas RJ, Estes LA
and Suthipinijtham P: Synergy of irofulven in combination with
other DNA damaging agents: Synergistic interaction with
altretamine, alkylating, and platinum-derived agents in the MV522
lung tumor model. Cancer Chemother Pharmacol. 63:19–26. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tacconi EM, Badie S, De Gregoriis G,
Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña
Torres J, et al: Chlorambucil targets BRCA1/2-deficient tumours and
counteracts PARP inhibitor resistance. EMBO Mol Med. 11:e99822019.
View Article : Google Scholar : PubMed/NCBI
|
